TMO financials
Thermo Fisher Scientific Inc. · end-of-day data as of Oct 16, 2026
Thermo Fisher Scientific Inc.
$690.00+21.5%
Buy · 29 analystsPT $667.12 -3.3%
TMO reported revenue of $11.99B for the quarter ended Jun 27, 2026 (Q2 FY2026), up 10.5% from a year earlier. It posted diluted EPS of $4.68, free cash flow of $1.68B and a net margin of 14.5%.
Valuation
- P/E37.1x
- P/E vs own+31.3%
- P/E vs sector+31.8%
- FCF yield+2.9%
- Market cap$255B
Quarterly results
Q2 FY2026: Revenue +10.5% year over year, free cash flow 14.0% of revenue, operating margin 17.4%.
RevenueFree cash flow
| Q2 FY2026 | Jun 27, 2026 | $11.99B | 4.68 | $1.68B | 41.2% | 17.4% | 14.5% |
| Q1 FY2026 | Mar 28, 2026 | $11.01B | 4.43 | $816M | 40.7% | 16.9% | 15.0% |
| Q4 FY2025 | Dec 31, 2025 | $12.21B | 5.21 | $2.99B | 41.0% | 18.8% | 16.2% |
| Q3 FY2025 | Sep 27, 2025 | $11.12B | 4.27 | $1.83B | 41.2% | 18.7% | 14.5% |
| Q2 FY2025 | Jun 28, 2025 | $10.85B | 4.28 | $1.1B | 40.6% | 17.7% | 14.9% |
| Q1 FY2025 | Mar 29, 2025 | $10.36B | 3.98 | $361M | 41.0% | 17.8% | 14.5% |
| Q4 FY2024 | Dec 31, 2024 | $11.39B | 4.78 | $2.81B | 39.2% | 19.9% | 16.1% |
| Q3 FY2024 | Sep 28, 2024 | $10.6B | 4.24 | $1.89B | 41.0% | 18.1% | 15.4% |
| Q2 FY2024 | Jun 29, 2024 | $10.54B | 4.04 | $1.66B | 41.2% | 16.7% | 14.7% |
| Q1 FY2024 | Mar 30, 2024 | $10.35B | 3.46 | $904M | 40.8% | 16.6% | 12.8% |
| Q4 FY2023 | Dec 31, 2023 | $10.89B | 4.20 | $3.32B | 36.3% | 18.3% | 15.0% |
| Q3 FY2023 | Sep 30, 2023 | $10.57B | 4.42 | $2.08B | 41.0% | 18.7% | 16.2% |